CStone announces first patient dosed with anti-CTLA-4 antibody CS1002 of a Phase I study in Australia
SUZHOU, China, May 4, 2018 /PRNewswire/ — CStone Pharmaceuticals (Suzhou) Co., Ltd., (CStone) today announced dosing of the first patient of a Phase I clinical trial in Australia for CS1002,…